Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow REGENXBIO Inc.

Get SEC filing alerts via email and in your feed for REGENXBIO Inc.

RGNX

REGENXBIO Inc.

About REGENXBIO Inc.

Regenxbio Inc. is a biotechnology company specializing in gene therapy using its proprietary NAV® AAV vector platform. It develops investigational treatments for retinal, neuromuscular, and neurodegenerative diseases, delivering functional genes to address genetic defects. The company partners with industry leaders, licenses its platform to others, and focuses on scalable manufacturing and innovative delivery devices to provide long-lasting, potentially curative therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from REGENXBIO Inc.

1
1
REGENXBIO Inc. REGENXBIO Reports $90.1 Million Net Loss and Revenue Decline in Latest Quarter

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
REGENXBIO Inc. REGENXBIO Reports $170.4M Revenue Growth and $193.9M Net Loss in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
REGENXBIO Inc. REGENXBIO Reports 23% Revenue Growth to $29.7 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
REGENXBIO Inc. REGENXBIO Reports Q2 2025 Financial Results with $21.4M Revenue and $70.9M Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
REGENXBIO Inc. REGENXBIO Reports $89M Revenue and $6.1M Net Income in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
REGENXBIO Inc. REGENXBIO Reports $83.3 Million Revenue for Fiscal Year 2024, Down from $90.2 Million in 2023

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
REGENXBIO Inc. REGENXBIO Reports Decline in Revenues, Net Loss, and Improved Cash Position in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments